November 11, 2021
The recently initiated European research project 3D’omics aims to develop technology to analyze host-microbiota interactions at microscale. Afekta’s role in the project is to further develop and provide our non-targeted metabolomics method to analyze metabolic interactions between the gut microbiota and the host. The project is led by Assoc. Prof. Antton Alberdi (University of Copenhagen), and the consortium includes eight universities/research institutions and five companies. The project received ≈10 million € over the next four years from EU Horizon 2020, with Afekta’s share ≈ 900 000 €.
The 3D’omics project aims to minimize the impact of major challenges related to large-scale animal production, such as use of antibiotics and waste production by understanding the interactions between animals and microorganisms at the microscale by applying various omics technologies. Optimal interaction between the microbiota and the host can contribute to preventing diseases by boosting immunity and leading to reduced use of drugs like antibiotics.
“3D’omics project is a good opportunity for us to further develop our know-how and methodology in analyzing microbiota-associated metabolites in different biological systems and in different sample materials. Moreover, this project nicely complements the ongoing work in Afekta, like the EU Horizon 2020 BestTreat project, where we investigated the role of gut microbiota associated metabolites in health and disease.” says Dr. Olli Kärkkäinen, CEO of Afekta.
Short interview by Business Kuopio about experiences on participating in EU Horizon projects as a SME partner (in Finnish): https://www.businesskuopio.fi/uutiset/case-afekta-technologies-mukana-partnerina-kahdessa-h2020-ohjelmasta-rahoitetussa-hankkeessa/